<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00251004</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001A2309</org_study_id>
    <nct_id>NCT00251004</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients</brief_title>
  <official_title>Efficacy and Safety Study Comparing Concentration-controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare the safety and efficacy of three immunosuppressive
      treatment regimens following a kidney transplant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Composite Efficacy Endpoints - 12 Month Analysis</measure>
    <time_frame>12 months</time_frame>
    <description>The primary efficacy endpoint was the 12 month analysis of primary efficacy failure defined as a composite endpoint including treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up. A treated BPAR episode was defined as a biopsy graded IA, IB, IIA, IIB, or III that was treated with anti-rejection therapy. Graft loss was defined as the allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis as well as re-transplant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-inferiority Analysis on Percentage of Participants With Composite Efficacy Endpoints</measure>
    <time_frame>12 months</time_frame>
    <description>The primary efficacy endpoint was the 12 month analysis of primary efficacy failure defined as a composite endpoint including treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up. In the definition of composite efficacy failure, loss to follow-up includes patients who did not experience treated BPAR, graft loss or death on or after day 1 and whose last day of contact was prior to day 316, the start day of the 12 month visit window.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With the Composite Incidence of Graft Loss, Death or Loss to Follow up at 12 Months Post-transplantation</measure>
    <time_frame>12 months</time_frame>
    <description>Graft loss was defined as graft loss (the allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis) and re-transplant.
A loss to follow-up patient in the composite endpoint of graft loss, death or loss to follow-up (the main secondary efficacy endpoint) was a patient who did not experience graft loss or death from day 1 and whose last day of contact was prior to study day 316.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-inferiority Analysis of Renal Function, Calculated by Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula</measure>
    <time_frame>at 12 months</time_frame>
    <description>Modification of Diet in Renal Disease (MDRD) formula is:
GFR [mL/min/1.73m^2] = 186.3*(C^-1.154)*(A^-0.203)*G*R where
C is the serum concentration of creatinine [mg/dL],
A is patient age at sample collection date [years],
G=0.742 when gender is female, otherwise G=1,
R=1.21 when race is black, otherwise R=1</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">833</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Graft Rejection</condition>
  <arm_group>
    <arm_group_label>Low-dose Everolimus Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Everolimus Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.44 g Mycophenolic Acid (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>oral, bis in diem/twice a day (bid)</description>
    <arm_group_label>Low-dose Everolimus Group</arm_group_label>
    <arm_group_label>High-dose Everolimus Group</arm_group_label>
    <other_name>Certican, Zotress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolic Acid (MPA)</intervention_name>
    <description>2 oral capsules of mycophenolic acid 360mg administered bid</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Myfortic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine A (CsA)</intervention_name>
    <description>CsA dose adjustments were based on CsA trough levels (C0).</description>
    <arm_group_label>Low-dose Everolimus Group</arm_group_label>
    <arm_group_label>High-dose Everolimus Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Neoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab</intervention_name>
    <description>All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.</description>
    <arm_group_label>Low-dose Everolimus Group</arm_group_label>
    <arm_group_label>High-dose Everolimus Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Simulect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <description>Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.</description>
    <arm_group_label>Low-dose Everolimus Group</arm_group_label>
    <arm_group_label>High-dose Everolimus Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients of any race between 18 to 70 years old (inclusive)

          -  Patients who gave written informed consent to participate in the study

        Exclusion Criteria:

          -  Recipients of multi-organ transplantation

          -  Recipients of a primary cadaveric or primary non-human leucocyte antigen (HLA)
             identical living donor kidney transplantation.

          -  Graft cold ischemia time greater than 40 hours.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2005</study_first_submitted>
  <study_first_submitted_qc>November 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2005</study_first_posted>
  <results_first_submitted>December 17, 2010</results_first_submitted>
  <results_first_submitted_qc>April 7, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 10, 2011</results_first_posted>
  <last_update_submitted>April 7, 2011</last_update_submitted>
  <last_update_submitted_qc>April 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Novartis</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Renal transplantation, kidney, and organ transplant</keyword>
  <keyword>Renal transplant rejection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low-dose Everolimus Group</title>
          <description>1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
        </group>
        <group group_id="P2">
          <title>High-dose Everolimus Group</title>
          <description>3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
        </group>
        <group group_id="P3">
          <title>Control Group</title>
          <description>1.44 g Mycophenolic Acid (MPA) (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="277"/>
                <participants group_id="P2" count="279"/>
                <participants group_id="P3" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>12 Month Analysis</title>
              <participants_list>
                <participants group_id="P1" count="241">Under 12 month analysis under group 1, 179 Completed study medication.</participants>
                <participants group_id="P2" count="249">Under 12 month analysis under group 2, 175 Completed study medication.</participants>
                <participants group_id="P3" count="253">Under 12 month analysis under group 3, 200 Completed study medication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>24 Month Analysis</title>
              <participants_list>
                <participants group_id="P1" count="232">Under 24 month analysis under group 1, 167 Completed study medication.</participants>
                <participants group_id="P2" count="238">Under 24 month analysis under group 2, 161 Completed study medication.</participants>
                <participants group_id="P3" count="246">Under 24 month analysis under group 3, 185 Completed study medication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="232"/>
                <participants group_id="P2" count="238"/>
                <participants group_id="P3" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Graft Loss</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low-dose Everolimus Group</title>
          <description>1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
        </group>
        <group group_id="B2">
          <title>High-dose Everolimus Group</title>
          <description>3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
        </group>
        <group group_id="B3">
          <title>Control Group</title>
          <description>1.44 g Mycophenolic Acid (MPA) (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="277"/>
            <count group_id="B2" value="279"/>
            <count group_id="B3" value="277"/>
            <count group_id="B4" value="833"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.7" spread="12.72"/>
                    <measurement group_id="B2" value="45.3" spread="13.36"/>
                    <measurement group_id="B3" value="47.2" spread="12.74"/>
                    <measurement group_id="B4" value="46.1" spread="12.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="189"/>
                    <measurement group_id="B4" value="557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Composite Efficacy Endpoints - 12 Month Analysis</title>
        <description>The primary efficacy endpoint was the 12 month analysis of primary efficacy failure defined as a composite endpoint including treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up. A treated BPAR episode was defined as a biopsy graded IA, IB, IIA, IIB, or III that was treated with anti-rejection therapy. Graft loss was defined as the allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis as well as re-transplant.</description>
        <time_frame>12 months</time_frame>
        <population>Intention-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Everolimus Group</title>
            <description>1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
          </group>
          <group group_id="O2">
            <title>High-dose Everolimus Group</title>
            <description>3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>1.44 g Mycophenolic Acid (MPA) (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Efficacy Endpoints - 12 Month Analysis</title>
          <description>The primary efficacy endpoint was the 12 month analysis of primary efficacy failure defined as a composite endpoint including treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up. A treated BPAR episode was defined as a biopsy graded IA, IB, IIA, IIB, or III that was treated with anti-rejection therapy. Graft loss was defined as the allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis as well as re-transplant.</description>
          <population>Intention-to-treat (ITT) population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite Endpoint (n)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>--Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>--Graft Loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>--Treated BPAR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>--Lost to follow up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With the Composite Incidence of Graft Loss, Death or Loss to Follow up at 12 Months Post-transplantation</title>
        <description>Graft loss was defined as graft loss (the allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis) and re-transplant.
A loss to follow-up patient in the composite endpoint of graft loss, death or loss to follow-up (the main secondary efficacy endpoint) was a patient who did not experience graft loss or death from day 1 and whose last day of contact was prior to study day 316.</description>
        <time_frame>12 months</time_frame>
        <population>Intention-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Everolimus Group</title>
            <description>1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
          </group>
          <group group_id="O2">
            <title>High-dose Everolimus Group</title>
            <description>3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>1.44 g Mycophenolic Acid (MPA) (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With the Composite Incidence of Graft Loss, Death or Loss to Follow up at 12 Months Post-transplantation</title>
          <description>Graft loss was defined as graft loss (the allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis) and re-transplant.
A loss to follow-up patient in the composite endpoint of graft loss, death or loss to follow-up (the main secondary efficacy endpoint) was a patient who did not experience graft loss or death from day 1 and whose last day of contact was prior to study day 316.</description>
          <population>Intention-to-treat (ITT) population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="9.7"/>
                    <measurement group_id="O3" value="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Everolimus is non-inferior to mycophenolic acid (MPA) if the upper limit of the 95% confidence interval for the difference in combined graft loss, death or loss to follow-up rates is &lt;10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin was set at 10%.</non_inferiority_desc>
            <p_value>0.001</p_value>
            <p_value_desc>To control for multiple comparisons, the two-sided significance level was set at 0.025.</p_value_desc>
            <method>Z-test</method>
            <param_type>Difference in percentage</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Everolimus is non-inferior to MPA if the upper limit of the 95% confidence interval for the difference in combined graft loss, death or loss to follow-up rates is &lt;10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin was set at 10%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>To control for multiple comparisons, the two-sided significance level was set at 0.025.</p_value_desc>
            <method>Z-test</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>5.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-inferiority Analysis on Percentage of Participants With Composite Efficacy Endpoints</title>
        <description>The primary efficacy endpoint was the 12 month analysis of primary efficacy failure defined as a composite endpoint including treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up. In the definition of composite efficacy failure, loss to follow-up includes patients who did not experience treated BPAR, graft loss or death on or after day 1 and whose last day of contact was prior to day 316, the start day of the 12 month visit window.</description>
        <time_frame>12 months</time_frame>
        <population>Intention-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Everolimus Group</title>
            <description>1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
          </group>
          <group group_id="O2">
            <title>High-dose Everolimus Group</title>
            <description>3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>1.44 g Mycophenolic Acid (MPA) (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inferiority Analysis on Percentage of Participants With Composite Efficacy Endpoints</title>
          <description>The primary efficacy endpoint was the 12 month analysis of primary efficacy failure defined as a composite endpoint including treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up. In the definition of composite efficacy failure, loss to follow-up includes patients who did not experience treated BPAR, graft loss or death on or after day 1 and whose last day of contact was prior to day 316, the start day of the 12 month visit window.</description>
          <population>Intention-to-treat population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1"/>
                    <measurement group_id="O2" value="21.5"/>
                    <measurement group_id="O3" value="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Everolimus is non-inferior to mycophenolic acid (MPA) if the upper limit of the 95% confidence interval for the difference in percentage of participants composite efficacy failure is &lt;10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin was set at 10%.</non_inferiority_desc>
            <p_value>0.014</p_value>
            <p_value_desc>To control for multiple comparisons, the two-sided significance level was set at 0.025.</p_value_desc>
            <method>Z - test</method>
            <param_type>Difference in percentage</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Everolimus is non-inferior to MPA if the upper limit of the 95% confidence interval for the difference in composite efficacy failure rates is &lt;10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin was set at 10%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>To control for multiple comparisons, the two-sided significance level was set at 0.025.</p_value_desc>
            <method>Z-test</method>
            <param_type>Difference in percentage</param_type>
            <param_value>-3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.8</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-inferiority Analysis of Renal Function, Calculated by Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula</title>
        <description>Modification of Diet in Renal Disease (MDRD) formula is:
GFR [mL/min/1.73m^2] = 186.3*(C^-1.154)*(A^-0.203)*G*R where
C is the serum concentration of creatinine [mg/dL],
A is patient age at sample collection date [years],
G=0.742 when gender is female, otherwise G=1,
R=1.21 when race is black, otherwise R=1</description>
        <time_frame>at 12 months</time_frame>
        <population>Intention to treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Everolimus Group</title>
            <description>1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
          </group>
          <group group_id="O2">
            <title>High-dose Everolimus Group</title>
            <description>3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>1.44 g Mycophenolic Acid (MPA) (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inferiority Analysis of Renal Function, Calculated by Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula</title>
          <description>Modification of Diet in Renal Disease (MDRD) formula is:
GFR [mL/min/1.73m^2] = 186.3*(C^-1.154)*(A^-0.203)*G*R where
C is the serum concentration of creatinine [mg/dL],
A is patient age at sample collection date [years],
G=0.742 when gender is female, otherwise G=1,
R=1.21 when race is black, otherwise R=1</description>
          <population>Intention to treat (ITT) population.</population>
          <units>mL/min/1.73m^2</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="277"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.66" lower_limit="-1.6"/>
                    <measurement group_id="O2" value="51.41" lower_limit="-4.9"/>
                    <measurement group_id="O3" value="52.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis: the mean GFR of the everolimus arm is lower (worse) than that of the MPA arm by 8 mL/min/1.73m^2 or more.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin was set at -8 mL/min/1.73m^2.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>To control for multiple comparisons, the two-sided significance level was set at 0.025.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis: the mean GFR of the everolimus arm is lower (worse) than that of the MPA arm by 8 mL/min/1.73m^2 or more.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin was set at -8 mL/min/1.73m^2.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>To control for multiple comparisons, the two-sided significance level was set at 0.025.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.9</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At 24 month</time_frame>
      <desc>Safety population</desc>
      <group_list>
        <group group_id="E1">
          <title>Low-dose Everolimus Group</title>
          <description>1.5 mg everolimus (one 0.75-mg tablet bis in diem/twice a day (bid)) + basiliximab + reduced-dose Cyclosporine A (CsA) ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
        </group>
        <group group_id="E2">
          <title>High-dose Everolimus Group</title>
          <description>3.0 mg everolimus (two 0.75-mg tablets bid) + basiliximab + reduced-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a trough (C0) value within the pre-specified target ranges: starting at the day 5 visit: 100-200 ng/mL, starting at the month 2 visit: 75-150 ng/mL, starting at the month 4 visit: 50-100 ng/mL and starting at the month 6 visit: 25-50 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
        </group>
        <group group_id="E3">
          <title>Control Group</title>
          <description>1.44 g Mycophenolic Acid (two 360-mg tablets bid) + basiliximab + standard-dose CsA ± corticosteroids.
The CsA dose was adjusted to attain a C0 value within the following range for the time of the study: starting at the day 5 visit: 200-300 ng/mL, starting at the month 2 visit and thereafter: 100-250 ng/mL. Patients received their first dose of basiliximab within 2 hours prior to transplant surgery and on day 4 post-transplant or according to local practice. Corticosteroids were administered according to local therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="176" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="193" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="168" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Haemolytic uraemic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Methaemoglobinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism tertiary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dieulafoy's vascular malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Localised intraabdominal fluid collection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Oesophagitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Oesophagitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pancreatic pseudocyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Sclerosing encapsulating peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Thrombosis mesenteric vessel</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Implant site effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anti-neutrophil cytoplasmic antibody positive vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Kidney transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Serum sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Coccidioidomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Infected lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Parvovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Perinephric abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Polyomavirus-associated nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pulmonary mycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Stent related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>West Nile viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Gastrointestinal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Incision site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Perinephric collection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Perirenal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Post procedural discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Post procedural urine leak</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pubic rami fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Renal graft loss</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Renal lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Transplant failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Ureteric anastomosis complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urinary anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urinary bladder rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Blood phosphorus increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Chest X-ray abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hormone level abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus associated lymphoproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lip neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Primitive neuroectodermal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Neurodegenerative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Neuromyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Stupor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Focal segmental glomerulosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis rapidly progressive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>IgA nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Renal artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Renal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Renal tubular atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Residual urine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Ureteral necrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urethral disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urinary fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa uteri mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Alveolar proteinosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Nasal septum perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lymphorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Steal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Subclavian vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="268" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="272" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="264" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="116" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="116" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Complications of transplant surgery</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Perinephric collection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Post procedural discharge</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hirsutism</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="274"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="278"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

